ASP Isotopes 10-K and Business Updates
4/14/26
SEQH CAPITAL RESEARCH – TEAR SHEET
ASPI ISOTOPES (ASPI) – FY2025 10‑K & BUSINESS UPDATE PREVIEW
WHAT THIS REPORT ANSWERS
The report distills ASP Isotopes’ FY2025 10‑K and April 2026 business update into a clean institutional read‑through: how the business mix actually looks, how much of the $175M loss is economic vs accounting noise, and what has to go right to get anywhere near the >$300M EBITDA target by 2031.
It walks through segment economics (specialist isotopes, nuclear fuels/QLE, Skyline construction), the Renergen helium acquisition, QLE’s planned IPO/royalty structure, and six non‑obvious angles that matter for serious capital.
CORE SNAPSHOT & SEGMENT REALITY
2025 revenue jumped +475% to $23.8M, but 76% of that came from Skyline’s Hong Kong construction business; core isotope enrichment was still effectively pre‑revenue (radiopharmacy only).
Net loss of $175.1M is dominated by a $123.7M non‑cash fair value hit on QLE convertible notes; stripping that out leaves a ~$59.9M operating loss tied to deliberate R&D and platform build‑out.
Cash and short‑term investments sit at $333M, versus FY25 operating cash burn of ~$37.8M, implying 8–9 years of runway at that burn rate before Renergen Phase 2 capex and additional plants.
BUSINESS PILLARS – WHAT’S REALLY DRIVING VALUE
Specialist isotopes: Radiopharmacy revenue of $5.7M (+46% YoY) with segment assets ballooning to $323.7M as three enrichment plants move toward 2026 commercial launches for Si‑28, C‑14, and Yb‑176.
Nuclear fuels (QLE): Zero revenue in 2025, but QLE has TerraPower HALEU supply agreements (up to 150 MT over 10 years), NECSA site access, a TerraPower/Kairos‑trained CTO, and a confidential S‑1 filed in Nov 2025; ASPI expects to retain a 10% perpetual royalty, EPC contracts, and distribute equity on IPO.
Construction / Skyline: $18.2M revenue and $17.5M net income at ~96% margin, a clearly anomalous but profitable segment used as an acquisition vehicle (stakes in Remag and a Kazakhstan critical‑minerals entity).
Renergen: Acquired Jan 2026 with 14.27M ASPI shares; Phase 1 helium/LNG (58 MCF/d helium, 2,500 GJ/d LNG) targets Q3 2026, with a >10x Phase 2 scale‑up contingent on funding and 44‑month build.
THE $300M+ EBITDA TARGET – WHAT HAS TO WORK
Management’s “> $300M EBITDA by 2031” is framed as aspirational, not formal guidance; SEQH decomposes it into building blocks:
Helium/LNG (Renergen Phase 1/2): ~$100–150M
Si‑28 & other isotopes: ~$50–100M
Radiopharmacy roll‑up: ~$30–50M
QLE 10% royalty: ~$50–100M
C‑14, Yb‑176, and other isotopes: ~$20–50M
Hitting that bridge requires simultaneous commercialization of 3+ verticals within five years, with helium the most de‑risked near‑term contributor and QLE separation the largest “hidden value” lever if executed.
NON‑OBVIOUS ANGLES & KEY RISKS
Convertible note optics: P&L dominated by non‑cash fair value remeasurement; SEQH argues JSE‑style adjusted EPS is the right metric for tracking operational progress.
QLE IPO optionality: A 10% perpetual royalty, EPC fees, and equity distribution could rerate ASPI’s nuclear‑fuels exposure even at modest QLE revenue levels, especially in a thin HALEU market currently dominated by Centrus.
South Africa concentration: All enrichment plants, PET Labs, and Renergen sit in South Africa, layering Eskom grid instability, power‑surge incidents (one damaged laser already), and political/currency risk on top of execution risk.
Radiopharmacy roll‑up: Quiet but important—U.S. pharmacy acquisitions plus a PET Labs buyout option provide a cash‑generating floor while higher‑beta isotope and QLE pieces scale.
SBC and dilution: ~$16M SBC (86% YoY growth) now exceeds gross profit and sits at ~27% of opex; combined with 2025 equity raises, share count has jumped from 72.1M to 125.9M (post‑Renergen).
WHAT PAID MEMBERS GET IN THE FULL REPORT
Upgrade to access the full ASPI FY2025 10‑K & Business Update filing analysis, including:
Full segment‑level models for specialist isotopes, QLE, Skyline/critical‑minerals, and Renergen, with pro‑forma views that strip out non‑cash FV noise.
A detailed bridge from today’s revenue mix to the >$300M EBITDA target, plus scenario tables showing what happens if only 1–2 major platforms fully commercialize.
Deep dives on QLE’s IPO/royalty structure, South Africa risk, radiopharmacy roll‑up economics, cash runway math, and SBC/dilution impact for institutional position‑sizing.
A 2026–2027 catalyst calendar covering Si‑28/C‑14/Yb‑176 first shipments, Phase 1 helium nameplate, QLE S‑1 public filing, radiopharmacy M&A cadence, and Renergen Phase 2 FID/financing.
Q2 / EASTER PROMO – 20% OFF YEARLY FOR LIFE
For investors who want ongoing access to filing‑based work like this ASPI 10‑K review, plus our nuclear, fuel‑chain, and critical‑minerals research, we’re running a limited Q2 / Easter promotion on our yearly subscription:
20% discount on the annual plan.
Locked “for life” as long as the subscription remains active.
Applies to all premium nuclear, helium, and isotope/nuclear‑fuels research going forward.
You can activate the promo and lock in the lifetime discount here:
Q2 / EASTER PROMO LINK
FULL 13-PAGE ASPI 10-K / BUSINESS ANALYSIS REPORT ATTACHED BELOW:
